CareDx Announces Closing of Public Offering of Common Stock

June 15, 2020

Palo Alto – Paul Hastings LLP, a leading global law firm, announced today that the firm represented CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, in an underwritten public offering (the “Offering”) of $125 million in shares of common stock. CareDx has granted the underwriters a 30-day option to purchase up to an additional approximately $18.75 million in shares, solely to cover over-allotments. CareDx intends to use the proceeds from the offering for working capital and general corporate purposes.

Goldman Sachs & Co. LLC and Jefferies LLC acted as joint book-running managers for the offering.

Corporate partners Jeff Hartlin and Elizabeth Razzano led the Paul Hastings team, which also included associates Stephen Bandrowsky and Tyler Dodge.

At Paul Hastings, our purpose is clear — to help our clients and people navigate new paths to growth. With a strong presence throughout Asia, Europe, Latin America, and the U.S., Paul Hastings is recognized as one of the world’s most innovative global law firms.